मैत्रेय
Multi Superspeciality Hospital & Research Centre
Healing by Heart

May 30, 2025

To,

National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E),
Mumbai- 400051

Script Name: MAITREYA

ISIN: INE0PLQ01011

Sub: Outcome of the Board Meeting held on Friday, 30th May, 2025

Dear Sir/Madam,

The Board of Directors of the Company at their meeting held today i.e. May 30, 2025, inter-alia considered and approved the followings:

1. Audited Standalone and Consolidated Financial Results for half year and year ended March 31, 2025. Pursuant to Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed herewith the following:

   (a) Statement of Audited Standalone and Consolidated Financial Results for the half year and year ended March 31, 2025.

   (b) Audit Reports, issued by Statutory Auditors of the Company, on the Audited Financial Results of the Company for the half year and year ended March 31, 2025.

   (c) A confirmation pursuant to regulation 33(3) (d) of SEBI (LODR) Regulations 2015 from the CFO of the Company, declaring that the statutory auditors have expressed an unmodified audit opinion in respect of financial results.

2. Took note of the resignation of Mr. Chandan Pratapbhai Chetnani (Membership No. A66496) from the position of Company Secretary & Compliance Officer w.e.f. the closure of business hours on 15th May, 2025.

3. Appointment of Ms. Kashish Surana (Membership No. A76674), as Company Secretary, Compliance Officer and Key Managerial Personnel with effect from 30th May, 2025.

The Board of Directors of the Company based on the recommendation of the Nomination and Remuneration Committee at its meeting held on 30th May, 2025, appointed Ms. Kashish Surana as Company Secretary, Compliance Officer and Key Managerial Personnel of the Company with immediate effect.

4. Re-appointment of M/s. Bhavesh Saraiya & Co., as the Internal Auditor of the Company for the financial year 2025-26.

5. Appointment of Jaisal Mohatta, Partner of JDM and Associates LLP, Practicing Company Secretaries (Firm Registration No. L2025GJ019100 / Peer Review Certificate No. 6787/2025) as Secretarial Auditor of the Company for the financial year 2025-26.

6. Redemption of 1,80,000 6% Non-Convertible Cumulative Redeemable Preference Shares.

The particulars / details with respect to the aforesaid change(s) as required under SEBI Circular No. SEBI/HO/CFD/CFDPoD1/P/CIR/2023/123 dated 13th July 2023 are enclosed as **Annexure A** and details with respect to re-appointment of Secretarial Auditor and Internal Auditor of the Company as **Annexure-B**.

The aforesaid Board Meeting commenced at 08:00 p.m. (IST) and concluded at 08:40 p.m. (IST).

We request you to kindly take the above on record.

Thanking You,

Yours faithfully,

For **Maitreya Medicare Limited**

Narendra Singh Tanwar
Managing Director & CFO
DIN: 08459007

Encl. as above

Annexure-A

Sr. No.	Details of event needs to be provided	Information of such event
1	Reason for change viz. appointment, ~~resignation, removal, death of otherwise~~	Due to vacancy in office of Company Secretary, Board has resolved to appoint Ms. Kashish Surana as Company Secretary and Compliance Officer with immediate effect.
2	Date of appointment	30/05/2025
3	Bried Profile (in case of appointment)	Ms. Kashish Surana is a Qualified Company Secretary with an experience of over 2 years in the field of Corporate Laws. She has reasonable experience and track record of managing compliances of Corporates.
4	Disclosure of relationship between directors (in case of appointment of a director)	Not Applicable

Annexure B

Sr. No.	Particulars	M/s. JDM and Associates LLP
1	Reason for change viz. ~~appointment,~~ reappointment, ~~resignation, removal, death of otherwise~~	Appointment of Jaisal Mohatta, Partner of JDM and Associates LLP, Peer Reviewed Firm of Company Secretaries in Practice (Firm registration number: L2025GJ019100), as Secretarial Auditors of the Company.
2	Date of ~~appointment~~/ re-appointment/~~cessation (as applicable) & term of appointment~~/reappointment	The Board at its meeting held on May 30, 2025, approved the Appointment of Jaisal Mohatta, Partner of JDM and Associates LLP as Secretarial Auditors, for the financial year 2025-26.
3	Term of ~~Appointment~~ /re-appointment	1 year
4	Brief Profile (in case of appointment)	JDM and Associates LLP (Firm Registration No. L2025GJ019100) is **Peer reviewed firm** and is an integrated corporate service firm focused on Corporate Laws & Secretarial Compliances, Due Diligence, Certifications, XBRL filing, Startup

		Consultancy Services, Regulatory Authority Services, Secretarial Audits, Corporate Governance Audit, IPO Pre-Post Due-diligence services and related matters.
5	Disclosure of Relationships between directors (in case of appointment of a director).	Not Applicable
6	Information as required pursuant to BSE Circular ref. no. LIST/COMP/14/ 2018-19 and NSE ref. no. NSE/CML/2018/24, dated June 20, 2018.	Not Applicable

Sr. No.	**Particulars**	**M/s. Bhavesh Saraiya & Co.**
1	Reason for change viz. ~~appointment,~~ reappointment, ~~resignation, removal, death of otherwise~~	To comply with the provisions of the Companies Act, 2013 & SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, upon recommendation of Audit Committee, the Board of Directors at its meeting held on 30th May, 2025, Re-Appointed M/s. Bhavesh Saraiya & Co. as Internal Auditor of the Company, for a period of 1 (One) year.
2	Date of ~~appointment~~/ re-appointment/~~cessation~~ (as applicable) & term of appointment/reappointment	Re-appointment of M/s. Bhavesh Saraiya & Co. as Internal Auditor of the Company, shall be for the financial year 2025-26.
3	Term of ~~Appointment~~ /re-appointment	1 Year
3	Brief Profile (in case of appointment)	M/s. Bhavesh Saraiya & Co., a firm of Chartered Accountant being the Internal Auditor of the Company is a good leader in assurance, tax, transaction and advisory services.
4	Disclosure of Relationships between directors (in case of appointment of a director).	Not Applicable

मैत्रेय
Multi Superspeciality Hospital & Research Centre
Healing by Heart

May 30, 2025

To,

National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E),
Mumbai- 400051

Script Name: MAITREYA

Dear Sir,

Sub: Declaration pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Amendment Regulation, 2016

I, Narendra Singh Tanwar, Chief Financial Officer of Maitreya Medicare Limited, having it Registered Office at Nr Someshwara Char Rasta, Um Road, Surat, Gujarat, India, 395007 hereby declare that the Statutory Auditors of the Company M/s. Saherwala & Co. have issue an Audit Report with unmodified opinion on the Annual Audited Financial Result of the Company (Standalone & Consolidation) for the half year and year ended on 31st March, 2025.

The Disclosure is given in compliance to Regulation 33(3)(d) of SEBI (LODR) Regulation, 2015 as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulation, 2016 vide circular No CIR/CFD/CMD/56/2016 dated 27th May, 2016.

Kind takes this declaration on your record.

Your Sincerely,
Maitreya Medicare Limited

Narendra Singh Tanwar
Managing Director & CFO
DIN: 08459007

Saherwala & Co.
CHARTERED ACCOUNTANTS

Member of:
ACURA
& Affiliates
Approved CA Network
Presence in :-
Bengaluru, Delhi, Mumbai, Chennai, Kolkata, Pune, Hyderabad, Patna, Mysuru, Khagaria, Belgavi, Tirupur, Jaipur, Kurnool, **Surat,** Ahmedabad, Vellore & Burdwan

INDEPENDENT AUDITOR'S REPORT

To the Members of MAITREYA MEDICARE LIMITED

Formerly known as MAITREYA MEDICARE PRIVATE LIMITED

Report on the Audit of the Standalone Financial Statements

1. We have audited the accompanying Standalone financial statements of Maitreya Medicare Limited (*Formerly known as Maitreya Medicare Private Limited)*, which comprise the balance sheet as at 31st March 2025, and the statement of profit and loss, statement of cash flows for the period then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Standalone Financial Statements

2. The management and Board of Directors of the Company are responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ('the act') with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with rule 7 of Companies (Accounts) Rules, 2014. This responsibility includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of

SAHERWALA & CO. SURAT Chartered Accountants

appropriate accounting policies; making judgments and estimates that are reasonable and prudent; design, implementation and maintenance of adequate internal financial controls, that are operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

3. Our responsibility is to express an opinion on these standalone financial statements based on our audit. We have considered the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under. We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

4. An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements, that give a true and fair view, in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Company's management and Board of Directors, as well as evaluating the overall presentation of the financial statements.



5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Opinion

6. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India of the state of affairs of the Company as at 31st March 2025, its profit/~~loss~~ and its cash flows for the period ended on that date.

Report on Other Legal and Regulatory Requirements

7. As required by the Companies (Auditor's Report) Order, 2020 issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, and on the basis of such checks of the books and records of the company as we considered appropriate and according to the information and explanations given to us, we give in the "Annexure A" a statement on the matters Specified in paragraphs 3 and 4 of the Order report as per this order.

8. As required by section 143(3) of the Act, we further report that:

a) we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;

b) in our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books;

c) the Balance Sheet, Statement of Profit and Loss, and Cash Flow Statement dealt with by this Report are in agreement with the books of account;

SAHERWALA & CO. SURAT Chartered Accountants

d) in our opinion, the aforesaid Standalone financial statements comply with the applicable Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules 2014.

e) on the basis of written representations received from the directors as on March 31, 2025, and taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2025, from being appointed as a director in terms of Section 164(2) of the Act.

f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".

g) In our opinion and to the best of our information and according to the explanations given to us, we report as under with respect to other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014:

   i. The Company does not have any legal pending court litigations which would impact its financial position; except cases under the consumer court filed by patients against various insurance companies in which company is co-respondent. (Please see Notes No. 31.24 to the Balance Sheet)

   ii. The Company did not have any long-term contracts including derivative contracts; as such the question of commenting on any material foreseeable losses thereon does not arise;



iii. There has not been an occasion in case of the Company during the period under report to transfer any sums to the Investor Education and Protection Fund. The question of delay in transferring such sums does not arise.

h) The company, has used such accounting software for maintaining its books of account which:

i. Has a built-in Feature of recording audit trail (edit log) facility and

ii. The audit trail has operated throughout the year for all transactions recorded in the software and

iii. The audit trail feature has not been tampered with.

iv. The audit trail has been preserved by the company as per the statutory requirements for record retention.

FOR SAHERWALA & CO
CHARTERED ACCOUNTANTS
FRN 108969W

PLACE: SURAT
DATE: 30.05.2025



ESMAYEEL O. SAHERWALA
PARTNER
M. No. 122386
UDIN: 25122386BMNXHG3478

Maitreya Medicare Limited
(Formerly known as "Maitreya Medicare Private Limited")
CIN - U24290GJ2019PLC107298

STATEMENT OF STANDALONE AUDITED RESULTS FOR THE HALF YEAR AND YEAR ENDED MARCH 31, 2025

	Particulars	Half year ended			For the year ended March 31, 2025	For the year ended March 31, 2024
		March 31, 2025	March 31, 2024	September 30, 2024		
		Audited	Audited	Unaudited	Audited	Audited
I	Revenue from operations	2,223.34	2,225.27	2,217.98	4,441.32	4,652.81
II	Other income	29.70	17.12	14.28	43.98	22.27
III	**Total Revenue (I + II)**	2,253.04	2,242.39	2,232.26	4,485.30	4,675.08
IV	**Expenses:**					
	(a) Cost of Raw Material Consumed	127.73	144.57	159.07	286.80	375.49
	(b) Purchase of Stock-in-Trade	325.66	296.66	260.63	586.29	546.77
	(c) Changes in inventories of stock-in-trade	-1.65	3.71	0.61	(1.03)	26.64
	(d) Employee benefits expense	278.32	235.01	243.55	521.88	475.19
	(e) Finance costs	37.09	35.24	38.35	75.44	73.90
	(f) Depreciation and amortization expense	71.14	63.04	63.46	134.59	125.59
	(g) Other expenses	1,278.01	1,370.96	1,281.08	2,559.09	2,612.66
	Total Expenses	2,116.30	2,149.19	2,046.75	4,163.06	4,236.24
V	**Profit before prior-period items and tax (III - IV)**	136.74	93.20	185.51	322.25	438.85
VI	**Prior-Period Items**			-		-
VII	**Profit before tax (V- VI)**	136.74	93.20	185.51	322.25	438.85
VIII	**Tax expense:**					
	(1) Current tax expense	30.99	20.69	49.77	80.75	119.94
	(2) Deferred tax expense/(credit)	-	0.41	1.13	1.13	1.53
	(3) Short/(Excess) provision of tax for earlier years	50.42	-	-	50.42	-
		81.41	21.10	50.90	132.29	121.46
	Dividend on Preference Shares			0		0
IX	**Profit from continuing operations (VII-VIII)**	55.33	72.10	134.61	189.96	317.39
X	**Paid-up Equity Share Capital (Face Value of ₹ 10/- each)**	677.60	677.60	677.60	677.60	677.60
XI	**Reserves excluding revaluation reserves as per balance sheet of previous accounting year**			-		
XII	**Earnings per Equity Share (Non-Annualised) :-**					
	Face Value of ₹ 10/- each					
	(Pre-bonus)					
	- Basic					
	- Diluted					
	(Post-bonus)					
	- Basic					
	- Diluted					

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
30th May 2025, Surat.
UDIN: 25122386BMNXHG3478

SAHERWALA & CO. SURAT Chartered Accountants

PRANAV THAKER
DIN- 0007602708
Wholetime Director

NARENDRA TANWAR
DIN - 0008459007
MD AND CFO

VIMAL PATEL
DIN- 08458999
Wholetime Director

KASHISH SURANA
M . NO. A76674
Company Secretary

MAITREYA MEDICARE LIMITED

(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)

BALANCE SHEET AS ON 31st March 2025

CIN No. - U24290GJ2019PTC107298

(Currency: Rs in '000')

Particulars	Note No.	As at 31st March 2025	As at 31st March 2024
I. EQUITY & LIABILITIES			
(1) Shareholders"s Funds			
a) Share capital	1	120923.000	121723.00
b) Reserve & Surplus	2	199840.509	180847.08
c) Money received against share warrants		.00	.00
(2) Share application money pending allotment		.00	.00
(3) Non-Current Liabilities			
a) Long-term Borrowings	3	19594.39	27035.23
b)Deffered tax liability (Net)	4	6953.09	6839.92
c)Other long term Liabilities		.00	.00
d)Long term Provisions		.00	.00
(4) Current Liabilities			
a) Short-term Borrowings	5	15743.74	13600.70
b) Trade payables		.00	.00
(A) total outstanding dues of micro enterprises and small enterprises; and	6	2876.46	4436.14
(B) total outstanding dues of creditors other than micro enterprises and small enterprises.		24936.68	19064.62
c) Other curent Liabilites	7	45193.12	19633.66
d) Short term Provisions	8	8075.47	11993.87
Total		444136.46	405174.22
II. Assets			
(1) Non-current assets			
(a) Property, Plant and Equipment and Intangible Assets			
(i) Property, Plant and Equipment	9	118212.25	109209.12
(ii) Intangible Assets		1444.88	166.29
b) Non Current Investments	10	75830.00	25924.10
c) Deffered tax asset (net)		.00	.00
d) Long term loans and advances	11	52238.23	41735.91
e) Other Non current assets	12	12722.21	18572.90
(2) Current assets			
a) Current Investments	13	422.15	10197.07
b) Inventories	14	4797.70	4685.09
c) Trade receivables	15	151849.82	130707.63
d) Cash & Cash equivalents	16	19090.00	56613.53
e) Short-term loans and advances	17	5019.33	1540.97
f) Other current assets	18	2509.88	5821.60
Total		444136.46	405174.22

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
30th May 2025, Surat.
UDIN: 25122386BMNXHG3478

SAHERWALA & CO. SURAT Chartered Accountants

For MAITREYA MEDICARE LIMITED

PRANAV THAKER
DIN- 0007602708
Wholetime Director

NARENDRA TANWAR
DIN - 0008459007
MD AND CFO

VIMAL PATEL
DIN- 08458999
Wholetime Director

KASHISH SURANA
M . NO. A76674
Company Secretary

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
CASH FLOW STATEMENT
CIN No. - U24290GJ2019PTC107298
(Currency: Rs in '000')

PARTICULARS		Year Ended 31-03-2025		Year Ended 31-03-2024	
A. Cash Flow from Operating Activities:					
Profit Before exceptional and extradinary items and tax			**32224.47**		**43882.99**
Adjustments for :					
Depreciation		13459.32		12559.25	
Interest Income		-694.52		-1245.61	
Gratuity		1676.59		1285.90	
Interest & Finance Charges Paid		7544.39		7389.84	
Profit on sale of Investment		-225.09		258.04	
Sundry Balance Write back		.00		11344.52	
			21760.69		31591.93
Operating Profit before Working Capital Changes			53985.16		75474.92
Adjustments for :					
Increase / Decrease in Inventories		-112.60		3300.00	
Increase / Decrease in Short-term loans and advances		-3478.37		1758.51	
Increase / Decrease in Trade Receivables		-21142.19		-49459.28	
Increase / Decrease in Trade Payables		4312.39		-12868.35	
Increase / Decrease in other Current Assets		3311.72		-1634.78	
Increase / Decrease in Other Non Current Assets		4174.10		-3067.30	
Increase/Decrease in Provision		-3918.40		-2818.33	
Increase/Decrease in short term Borrowings		2143.03		734.08	
Increase/Decrease in other current liabilities		25559.45	10849.14	3722.15	-60333.29
Cash Generated from Operations			64834.29		15141.63
Direct Taxes Paid (Net)		14547.08	14547.08	17725.00	17725.00
Net Cash inflow in Operating Activities		**Total A**	**50287.21**	**Total A**	**-2583.37**
B. Cash Flow from Investing Activities:					
Purchases of Fixed assets		-23741.04		-6798.15	
Purchase of Investment		-44205.896		-33679.79	
Capital Government Grant of Fixed Assets		.00		.00	
Loans given to Associates and Subsidiaries		-9073.30		-20730.00	
Loans given to Others		.00		.00	
Repayment of Loans given to Associates and Subsidiaries		.00		.00	
Interest Income		694.52		1245.61	
Gain on Sale of Investment		.00		.00	
Sale of Investment		4300.00	-72025.72	4300.00	-55662.33
Net Cash used in Investing Activities		**Total B**	**-72025.72**	**Total B**	**-55662.33**



C. Cash Flow from Financing Activities:					
Issue of Equity Capital		.00		18160.00	
Share Premium		.00		114445.07	
Dividend		.00		-3561.40	
Issue of Preference Shares		.00		.00	
Redemption of Preference shares		-800.00		-3400.00	
Repayment of Borrowing		-7440.83		-18610.29	
Interest & Finance Charges Paid		-7544.39	-15785.22	-7026.13	100007.26
Net Cash from Financing Activities		**Total C**	**-15785.22**	**Total C**	**100007.26**
Net increase /(decrease) in cash and cash equivalents (A+B+C)		**Total (A+B+C)**	**-37523.73**	**Total (A+B+C)**	**41761.56**
Opening Cash and Cash equivalents			56613.52		14851.96
Closing Cash and Cash equivalents			**19089.80**		**56613.52**

Notes :

(i) Figures in brackets represent outflow.

(ii) The above Cash Flow statement has been prepared under the indirect method set out in AS-3 notified under Section 133 of the Companies Act,2013

(iii) Cash and Cash Equivalents represent cash and bank balances.

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

SAHERWALA & CO. SURAT Chartered Accountants

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
30th May 2025, Surat.
UDIN: 25122386BMNXHG3478

For MAITREYA MEDICARE LIMITED

PRANAV THAKER	**NARENDRA TANWAR**
DIN- 0007602708	**DIN - 0008459007**
Wholetime Director	**MD AND CFO**
VIMAL PATEL	**KASHISH SURANA**
DIN- 08458999	**M . NO. A76674**
Wholetime Director	**Company Secretary**

Maitreya Medicare Limited
(Formerly known as "Maitreya Medicare Private Limited")
CIN - U24290GJ2019PLC107298
STATEMENT OF STANDALONE AUDITED RESULTS FOR THE HALF YEAR AND YEAR ENDED MARCH 31, 2025

Notes to audited standalone financial results

1 The above audited Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors in their respective meeting held on May 30, 2025.

2 The Results for the half year and year ended March 30, 2025 are reviewed by the statutory auditor of the company in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.


3 These financial results have been prepared in accordance with the recognition and measurement principles of Accounting Standards ("AS") prescribed section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and the other accounting principles generally accepted in India.

4 The figures for the half year ended March 31, 2025 are the audited published figures for the half year ended September 30, 2024 limited reveiwed by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.

5 The figures for the half year ended March 31, 2025 are balancing figure between unaudited figures in respect of the half year ended September 30, 2024 limited reveiwed by the statutory auditors and audited figures for the financial year ended March, 31,2025. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.

6 The figures for the half-year ended September 30, 2024 are unaudited published figures in respect of the half-year ended September 30, 2024 limited reveiwed by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.

7 The comparative results for the year ended March 31, 2025 have been audited or reviewed by the statutory auditors of the Company. The figures for the year ended March 31, 2025 are audited published figures in respect of the year ended March 31, 2025 audited by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.



Maitreya Medicare Limited
(Formerly known as "Maitreya Medicare Private Limited")
CIN - U24290GJ2019PLC107298
STATEMENT OF STANDALONE AUDITED RESULTS FOR THE HALF YEAR AND YEAR ENDED MARCH 31, 2025

Notes to audited standalone financial results

8 The comparative results for the year ended March 31, 2025 have been audited or reviewed by the statutory auditors of the Company. The figures for the year ended March 31, 2024 are audited published figures in respect of the year ended March 31, 2024 audited by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.

9 The Company is engaged in the business of providing healthcare services and products. Hence, the Company does not have more than one reportable segment in terms of AS 17 hence segment wise reporting is not applicable.

10 During the year ended March 31, 2024, the company has issued 18,16,000 equity shares of ₹ 10 each at a premium of ₹ 68 - ₹ 72 each by way of initial public offer ("IPO") and got listed on Emerge Platform of National Stock Exchange of India Limited on November 7, 2023.

11 The company has utilised proceeds from IPO as per the object clause of the prospectus as detailed below:

S. No.	Object of the Issue	Allocated Amount (₹ in Thousands)	Amount utilised till March 31, 2025 (₹ in Thousands)	Amount unutilised till March 31, 2025 (₹ in Thousands)	Remarks (if any)
1	Making investment through Equity in the subsidiary named 'Maitreya Hospital Private Limited' for setting up Hospital at Valsad, Gujarat.	75,000.00	75,000.00	-	
2	Redemption of part of issued Non-Convertible Redeemable Preference Shares	10,000.00	4,200.00	5,800.00	Remaining amount is kept with banks.
3	Funding the working capital requirements of the company	50,000.00	50,000.00	-	

SANERWALA & CO. SURAT Chartered Accountants

Maitreya Medicare Limited
(Formerly known as "Maitreya Medicare Private Limited")
CIN - U24290GJ2019PLC107298
STATEMENT OF STANDALONE AUDITED RESULTS FOR THE HALF YEAR AND YEAR ENDED MARCH 31, 2025

Notes to audited standalone financial results

4	General Corporate Expenses	7,445.60	7,445.60	-	
5	Public Issue Expenses	6,466.40	6,466.40	-	
Total		**148,912.00**	**143,112.00**	**5,800.00**	

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

SAHERWALA & CO. SURAT Chartered Accountants

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
30th May 2025, Surat.
UDIN: 25122386BMNXHG3478

PRANAV THAKER
DIN- 0007602708
Wholetime Director

VIMAL PATEL
DIN- 08458999
Wholetime Director

NARENDRA TANWAR
DIN - 0008459007
MD AND CFO

KASHISH SURANA
M . NO. A76674
Company Secretary

Saherwala & Co.
CHARTERED ACCOUNTANTS

Member of:
ACURA
& Affiliates
Approved CA Network
Presence in :-
Bengaluru, Delhi, Mumbai, Chennai, Kolkata, Pune, Hyderabad, Patna, Mysuru, Khagaria, Belgavi, Tirupur, Jaipur, Kurnool, **Surat,** Ahmedabad, Vellore & Burdwan

INDEPENDENT AUDITOR'S REPORT

To the Members of MAITREYA MEDICARE LIMITED

Formerly known as MAITREYA MEDICARE PRIVATE LIMITED

Report on the Audit of the Consolidated Financial Statements

1. We have audited the financial statements of Maitreya Medicare Limited (*Formerly known as Maitreya Medicare Private Limited)* and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), which comprise the Consolidated balance sheet as at 31st March 2025, and the Consolidated statement of profit and loss, the Consolidated Statement of Changes in Equity, Consolidated statement of cash flows for the period then ended, and notes to the Consolidated financial statements, including a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

2. The Holding Company's Board of Directors are responsible for the preparation of these consolidated financial statements in terms of the requirements of the Companies Act, ('the act') that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting

records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid;

Auditor's Responsibility

3. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

4. An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the consolidated financial statements, that give a true and fair view, in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on



whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Company's management and Board of Directors, as well as evaluating the overall presentation of the consolidated financial statements.

5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the consolidated financial statements.

Opinion

6. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Group as at 31st March 2025, and their consolidated profit/~~loss~~ and their consolidated cash flows for the period ended on that date.

Report on Other Legal and Regulatory Requirements

7. According to the information and explanations given to us, and based on the reports, issued by the auditors of the subsidiaries included in the consolidated financial statements of the Company, to which reporting on matters specified in paragraph 3 and 4 of the Order is applicable, provided to us by the Management of the Company and based on the identification of matters of qualifications or adverse remarks in their Companies (Auditor's Report) Order, 2020 reports by the respective component auditors and provided to us, we report that the auditors of such companies have not reported any qualifications or adverse remarks in their CARO reports.



8. As required by section 143(3) of the Act, we further report that:

a) we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;

b) in our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books;

c) the Consolidated Balance Sheet, Consolidated Statement of Profit and Loss, and Consolidated Cash Flow Statement dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements;

d) in our opinion, the aforesaid financial statements comply with the applicable Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules 2014.

e) on the basis of written representations received from the directors of the Holding Company as on 31st March, 2025 taken on record by the Board of Directors of the Holding Company and the reports of the statutory auditors of its subsidiary companies, incorporated in India, none of the directors of the Group companies, incorporated in India is disqualified as on 31st March, 2025 from being appointed as a director in terms of Section 164 (2) of the Act.

f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A".

g) In our opinion and to the best of our information and according to the explanations given to us, we report as under with respect to other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014:

i. The Company does not have any legal pending court litigations which would impact its financial position of the Group; except cases under the consumer court filed by

SAHERWALA & CO. SURAT Chartered Accountants

patients against various insurance companies in which company is co-respondent. (Please see Notes No. 32.24 to the Balance Sheet)

ii. The Company did not have any long-term contracts including derivative contracts; as such the question of commenting on any material foreseeable losses thereon does not arise;

iii. There has not been an occasion in case of the Company during the period under report to transfer any sums to the Investor Education and Protection Fund. The question of delay in transferring such sums does not arise.

h) The company, has used such accounting software for maintaining its books of account which:

i. Has a built-in Feature of recording audit trail (edit log) facility and

ii. The audit trail has operated throughout the year for all transactions recorded in the software and

iii. The audit trail feature has not been tampered with.

iv. The audit trail has been preserved by the company as per the statutory requirements for record retention.

FOR SAHERWALA & CO
CHARTERED ACCOUNTANTS
FRN 108969W

PLACE: SURAT
DATE: 30/05/2025

SAHERWALA & CO. SURAT Chartered Accountants

ESMAYEEL O. SAHERWALA
PARTNER
M. No. 122386
UDIN: 25122386BMNXHH3769

Maitreya Medicare Limited
(Formerly known as "Maitreya Medicare Private Limited")
CIN - U24290GJ2019PLC107298

STATEMENT OF CONSOLIDATED AUDITED RESULTS FOR THE HALF YEAR AND YEAR ENDED MARCH 31, 2025

	Particulars	Half Year ended			For the year ended	
		March 31, 2025	March 31, 2024	September 30, 2024	March 31, 2025	March 31, 2024
		Audited	Audited	Unaudited	Audited	Audited
I	Revenue from operations	2,229.92	2,300.99	2,436.28	4,666.20	4,780.35
II	Other income	39.62	22.07	18.98	58.60	27.22
III	**Total Revenue (I + II)**	2,269.54	2,323.06	2,455.26	4,724.80	4,807.57
IV	**Expenses:**					
	(a) Cost of Raw Material Consumed	128.11	145.55	159.07	287.17	376.69
	(b) Purchase of Stock-in-Trade	329.49	311.64	261.90	591.39	561.75
	(c) Changes in inventories of stock-in-trade	-7.14	1.12	4.66	(2.48)	24.05
	(d) Employee benefits expense	348.74	285.88	283.47	632.20	534.84
	(e) Finance costs	35.11	45.58	45.10	80.20	84.24
	(f) Depreciation and amortization expense	78.11	63.61	66.10	144.21	127.22
	(g) Other expenses	1,262.33	1,441.02	1,408.75	2,671.08	2,711.71
	Total Expenses	2,174.75	2,294.40	2,229.05	4,403.78	4,420.51
V	**Profit before prior-period items and tax (III - IV)**	94.79	28.66	226.21	321.02	387.06
VI	**Prior-Period Items**					
VII	**Profit before tax (V- VI)**	94.79	28.66	226.21	321.02	387.06
VIII	**Tax expense:**					
	(1) Current tax expense	24.89	18.93	57.83	82.72	119.94
	(2) Deferred tax expense/(credit)	-0.52	0.42	1.15	0.63	1.48
	(3) Short/(Excess) provision of tax for earlier years	50.42	-	-	50.42	-
		74.79	19.35	58.98	133.78	121.42
IX	**Profit from continuing operations (VII-VIII)**	**20.00**	**9.31**	**167.23**	**187.24**	**265.64**
X	**Minority Interest**					
XI	**Profit attributable to owners of the equity (IX-X)**	**20.00**	**9.31**	**167.23**	**187.24**	**265.64**
XII	**Paid-up Equity Share Capital (Face Value of ₹ 10/- each)**	677.60	677.60	677.60	677.60	677.60
XIII	**Reserves excluding revaluation reserves as per balance sheet of previous accounting year**					
XIV	**Earnings per Equity Share (Non-Annualised) :-**					
	Face Value of ₹ 10/- each					
	(Pre-bonus)					
	- Basic					
	- Diluted					
	(Post-bonus)					
	- Basic					
	- Diluted					

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
30th May 2025, Surat.
UDIN: 25122386BMNXHH3769

SAHERWALA & CO. SURAT Chartered Accountants

PRANAV THAKER
DIN- 0007602708
Wholetime Director

VIMAL PATEL
DIN- 08458999
Wholetime Director

NARENDRA TANWAR
DIN - 0008459007
MD AND CFO

KASHISH SURANA
M . NO. A76674
Company Secretary

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
CONSOLIDATED BALANCE SHEET AS ON 31st March 2025
CIN No. - U24290GJ2019PTC107298
(Currency: Rs in '000')

Particulars	Note No.	CONSOLIDATED AMOUNT As at 31st March 2025	CONSOLIDATED AMOUNT As at 31st March 2024
I. EQUITY & LIABILITIES			
(1) Shareholders"s Funds			
a) Share capital	1	121403	121723
b) Reserve & Surplus	2	199428	180704
c) Money received against share warrants	3		
d) Minorities Interest / Capital Reserve	3.1	7747	1096
(2) Share application money pending allotment			
(3) Non-Current Liabilities			
a) Long-term Borrowings	4	36348	43424
b)Deffered tax liability (Net)	5	7034	6971
c)Other long term Liabilities			
d)Long term Provisions			
(4) Current Liabilities			
a) Short-term Borrowings	6	15744	13601
b) Trade payables			
(A) total outstanding dues of micro enterprises and small enterprises; and small enterprises.	7	3295	4436
(B) total outstanding dues of creditors other than micro enterprises and small enterprises.		28867	26989
c) Other curent Liabilites	8	51805	27664
d) Short term Provisions	9	8272	11994
Total		479943	438602
II. Assets			
(1) Non-current assets			
(a) Property, Plant and Equipment			
(i) Gross Block	10	219621	195866
(ii) Depreciation		67024	52660
(iii) Net Block		152597	143206
b) Non Current Investments	11	10	4510
c) Deffered tax asset (net)			
d) Long term loans and advances	12	30489	23386
e) Other Non current assets	13	18442	14293
(2) Current assets			
a) Current Investments	14	422	10197
b) Inventories	15	5923	6070
c) Trade receivables	16	149565	136954
d) Cash & Cash equivalents	17	79163	65569
e) Short-term loans and advances	18	39789	28554
f) Other current assets	19	3542	5863
Total		479943	438602

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
30th, May, 2025, Surat
UDIN: 25122386BMNXHH3769

SAHERWALA & CO. SURAT Chartered Accountants

For MAITREYA MEDICARE LIMITED

PRANAV THAKER
DIN- 0007602708
Wholetime Director

NARENDRA TANWAR
DIN - 0008459007
MD AND CFO

VIMAL PATEL
DIN- 08458999
Wholetime Director

KASHISH SURANA
M . NO. A76674
Company Secretary

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
Statement of Consolidated Cash Flow Statement for the year ended 31st March 2025
CIN No. - U24290GJ2019PTC107298
(Currency: Rs in '000')

PARTICULARS		CONSOLIDATED AMOUNT As at 31st March 2025	CONSOLIDATED AMOUNT As at 31st March 2024
A. Cash Flow from Operating Activities:			
Net Profit before tax		32102	41553
Adjustments for :			
Depreciation		14421	12722
Interest Income		-2154	-1522
Interest & Finance Charges Paid		7984	8420
Gratuity		1677	1286
Profit on sale of Investment		225	258
Sundry Balance Write back			11345
	Sub Total	22153	32509
Operating Profit before Working Capital Changes		54255	74063
Adjustments for :			
Increase / Decrease in Inventories		147	3041
Increase / Decrease in Short-term loans and advances		-3478	1759
Increase / Decrease in Trade Receivables		-18444	-54606
Increase / Decrease in Trade Payables		6571	9564
Increase / Decrease in Other Current Assets		-619	-21503
Increase / Decrease in Other Non Current Assets		4174	-3067
Increase / Decrease in Long-term loans and advances		145	28
Increase/Decrease in Provision		-3918	-3038
Increase/Decrease in short term liabilites		2143	734
Increase/Decrease in Current Liability		24289	4839
	Sub Total	11009	-81378
Cash Generated from Operations		65264	-7315
Direct Taxes Paid (Net)		14695	17725
Net Cash inflow in Operating Activities	**Total A**	50568	-25040
B. Cash Flow from Investing Activities:			
Purchases of Property, Plant and Equipment		-23813	-16133
Purchase of Investment		-44656	-33846
Other Bank Balance			232
Capital Government Grant of Property, Plant and Equipment			
Loans given to Associates and Subsidiaries		-9073	-20730
Loans given to Others			-2500
Loans received from Holding compnay		-2621	12792
Interest Income		2154	1522
Gain on Sale of Investment			
Sale of Investment		4300	4300
		-73709	-54363
Net Cash used in Investing Activities	**Total B**	-73709	-54363
C. Cash Flow from Financing Activities:			
Issue of Equity Capital			19160
Share application Money received		51600	23500
Share Premium			114445
Dividend			-3561
Proceed of Borrowing		4783	
issue of Preference Shares			
Redemption of Preference shares		-2000	-4800
Repayment of Borrowing		-9665	-18610
Interest & Finance Charges Paid		-7984	-8057
		36735	122077
Net Cash from Financing Activities	**Total C**	36735	122077
Net increase /(decrease) in cash and cash equivalents (A+B+C)		13594	42674
Opening Cash and Cash equivalents		65569	22896
Closing Cash and Cash equivalents		79163	65569

Notes :
(i) Figures in brackets represent outflow.
(ii) The above Cash Flow statement has been prepared under the indirect method set out in AS-3 notified under Section 133 of the Companies Act,2013
(iii) Cash and Cash Equivalents represent cash and bank balances.

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
30th, May, 2025, Surat
UDIN: 25122386BMNXHH3769

SAHERWALA & CO. SURAT Chartered Accountants

For MAITREYA MEDICARE LIMITED

PRANAV THAKER	**NARENDRA TANWAR**
DIN- 0007602708	**DIN - 0008459007**
Wholetime Director	**MD AND CFO**
VIMAL PATEL	**VASHISH SURANA**
DIN- 08458999	**M . NO. A76674**
Wholetime Director	**Company Secretary**

Maitreya Medicare Limited
(Formerly known as "Maitreya Medicare Private Limited")
CIN - U24290GJ2019PLC107298
STATEMENT OF CONSOLIDATED AUDITED RESULTS FOR THE HALF YEAR AND YEAR ENDED MARCH 31, 2025

Notes to audited consolidated financial results

1 The above audited Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors in their respective meeting held on May 30, 2025.

2 The Results for the Half year and year ended March 31, 2025 are reviewed by the statutory auditor of the company in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements)

3 The results includes results of 2 wholly owned subsidiaries - Maitreya Hospital Private Limited and Maitreya Lifescience Private Limited and 1 subsidiary - Tulip Agility Private Limited.

4 These financial results have been prepared in accordance with the recognition and measurement principles of Accounting Standards ("AS") prescribed section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and the other accounting principles generally accepted in India.

5 The figures for the half year ended March 31, 2025 are balancing figure between unaudited figures in respect of the half year ended September 30, 2024 limited reveiwed by the statutory auditors and audited figures for the financial year ended March, 31,2025. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.

6 The figures for the half-year ended September 30, 2024 are unaudited published figures in respect of the half-year ended September 30, 2024 limited reveiwed by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.

7 The comparative results for the year ended March 31, 2025 have been audited or reviewed by the statutory auditors of the Company. The figures for the year ended March 31, 2025 are audited published figures in respect of the year ended March 31, 2025 audited by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.

8 The comparative results for the year ended March 31, 2025 have been audited or reviewed by the statutory auditors of the Company. The figures for the year ended March 31, 2024 are audited published figures in respect of the year ended March 31, 2024 audited by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.

9 The Company is engaged in the business of providing healthcare services and products. Hence, the Company does not have more than one reportable segment in terms of AS 17 hence segment wise reporting is not applicable.

10 During the preceding year ended March 31, 2024, the company has issued 18,16,000 equity shares of ₹ 10 each at a premium of ₹ 68 - ₹ 72 each by way of initial public offer ("IPO") and got listed on Emerge Platform of National Stock Exchange of India Limited on November 7, 2023.

SAHERWALA & CO. SURAT Chartered Accountants

Maitreya Medicare Limited
(Formerly known as "Maitreya Medicare Private Limited")
CIN - U24290GJ2019PLC107298
STATEMENT OF CONSOLIDATED AUDITED RESULTS FOR THE HALF YEAR AND YEAR ENDED MARCH 31, 2025

Notes to audited consolidated financial results

11 The company has utilised proceeds from IPO as per the object clause of the prospectus as detailed below:

S. No.	Object of the Issue	Allocated Amount (₹ in Thousands)	Amount utilised till March 31, 2025 (₹ in Thousands)	Amount unutilised till March 31, 2025 (₹ in Thousands)	Remarks (if any)
1	Making investment through Equity in the subsidiary named 'Maitreya Hospital Private Limited' for setting up Hospital at Valsad, Gujarat.	75,000.00	75,000.00	-	Remaining amount is kept with banks.
2	Redemption of part of issued Non-Convertible Redeemable Preference Shares	10,000.00	4,200.00	5,800.00	
3	Funding the working capital requirements of the company	50,000.00	50,000.00	-	
4	General Corporate Expenses	7,445.60	7,445.60	-	
5	Public Issue Expenses	6,466.40	6,466.40	-	
Total		**148,912.00**	**143,112.00**	**5,800.00**	

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

SAHERWALA & CO. SURAT Chartered Accountants

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
30th May 2025, Surat.
UDIN: 25122386BMNXHH3769

PRANAV THAKER
DIN- 0007602708
Wholetime Director

VIMAL PATEL
DIN- 08458999
Wholetime Director

NARENDRA TANWAR
DIN - 0008459007
MD AND CFO

KASHISH SURANA
M . NO. A76674
Company Secretary